Rating Change
Roth Capital analysts initiated coverage on Biodesix, Inc. (NASDAQ:BDSX) with a Buy rating on June 25, 2026.
new coverageNASDAQ:BDSX
Roth Capital Initiates Coverage on Biodesix, Inc. (BDSX) with Buy
Rating Change Roth Capital analysts initiated coverage on Biodesix, Inc. (NASDAQ:BDSX) with a Buy rating on June 25, 2026. Market Context Biodesix, Inc.
Market Context
Biodesix, Inc. operates in the Healthcare sector. The stock currently trades at $18.67 with a market capitalization of $58.4M.
Analyst coverage from Roth Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biodesix, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Biodesix, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 25, 2026 | Roth Capital | Buy | N/A |
| Jun 18, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 05, 2026 | Canaccord Genuity | Buy | N/A |
| Feb 27, 2026 | William Blair | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BDSX Stock Page
Frequently Asked Questions
What does a Buy rating mean for BDSX?
A Buy rating from Roth Capital reflects the analyst's outlook on Biodesix, Inc. (NASDAQ:BDSX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BDSX forecast page.
